about
Emerging drugs for uveitisBirdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatmentVisual Electrodiagnostic Testing in Birdshot ChorioretinopathyBirdshot retinochoroidopathyCurrent approach in the diagnosis and management of posterior uveitisPharmacotherapy for uveitis: current management and emerging therapy.Review of Systemic Immunosuppression for Autoimmune UveitisLong-term daclizumab therapy for the treatment of noninfectious ocular inflammatory diseaseClinical trials in noninfectious uveitisBirdshot uveitis: current and emerging treatment optionsUpdate on the use of systemic biologic agents in the treatment of noninfectious uveitis.Road to remission: a comprehensive review of therapy in uveitis.Biological agents for the treatment of uveitis.Pharmacotherapy of corneal transplantation.Systemic treatment of vitreous inflammation.New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment.In vitro end points for the assessment of cellular immune response-modulating drugs.Systemic treatments for noninfectious vitreous inflammation.A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.New pharmacotherapy options for noninfectious posterior uveitis.Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.Uveitic macular edema.Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy.
P2860
Q24630848-4C7D9331-FAE4-48CF-BF98-A8FF584235FFQ26749730-C7979176-9610-42E6-83B3-A95B2C806CA6Q26798181-3262E083-6227-4650-9FDE-75C4CDB3433AQ28080595-A9D9F01F-7F7F-4AF6-A69D-9B65E546E4BBQ30482534-6B5C93AE-6993-4432-8D2C-59BE3FB06A4DQ34274075-CF8D9A60-0BB5-44BF-BD1B-E303ACC7B7B4Q34627012-08446DB6-4E8F-4DCD-BC6A-D4A02C1AE968Q35215459-D55DBBE0-1904-457A-A462-6A5C16B1AE72Q35681664-6E89AB5F-F427-4D3A-BDDD-E06ACFED128CQ37412317-95B0C2F2-9466-4FE7-AC2E-4EA0E2B95D7EQ37600483-D3FE5F37-44EA-42C5-A9BA-CEB3AE520D45Q37936459-377795F8-E378-42C5-AC02-AC6521CA8CE3Q37984565-C30CD0DB-58DA-4F6F-9E56-49CD59110EFFQ37994335-D6E84A5F-47C6-4099-BD9C-619B23110987Q38048774-F6524AC4-9493-458B-B7F5-863B373F5568Q38057370-52DBBDBB-C163-41DF-908B-47F06FD815ACQ38088820-34C65807-BB61-4A4E-9B91-6CB0770E0A6AQ38172090-0F736EA4-F511-4045-907D-B38F45097488Q38250103-1EE829B2-C8DF-40C0-B606-36890E5CFF1EQ38253095-F0850A4C-1107-4EC2-8F2C-6A60DDDB5019Q38773144-85B51525-3928-480F-8904-9C85490DD780Q38852119-A2AA8208-712B-44C4-9002-CDA356768C4AQ48288484-844BAB5F-9CD6-49EA-9BFF-7DE1C92EA795
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Daclizumab for treatment of birdshot chorioretinopathy
@ast
Daclizumab for treatment of birdshot chorioretinopathy
@en
Daclizumab for treatment of birdshot chorioretinopathy
@nl
type
label
Daclizumab for treatment of birdshot chorioretinopathy
@ast
Daclizumab for treatment of birdshot chorioretinopathy
@en
Daclizumab for treatment of birdshot chorioretinopathy
@nl
prefLabel
Daclizumab for treatment of birdshot chorioretinopathy
@ast
Daclizumab for treatment of birdshot chorioretinopathy
@en
Daclizumab for treatment of birdshot chorioretinopathy
@nl
P2093
P3181
P1433
P1476
Daclizumab for treatment of birdshot chorioretinopathy
@en
P2093
C Stephen Foster
Chrysanthi Kafkala
John J Huang
Lucia Sobrin
William Christen
P304
P3181
P356
10.1001/ARCHOPHTHALMOL.2007.49
P407
P577
2008-02-01T00:00:00Z